|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0008377,
umls-concept:C0032105,
umls-concept:C0035647,
umls-concept:C0063695,
umls-concept:C0087111,
umls-concept:C0162621,
umls-concept:C0205216,
umls-concept:C0205250,
umls-concept:C0286651,
umls-concept:C0333348,
umls-concept:C0441889,
umls-concept:C0456962,
umls-concept:C0681850,
umls-concept:C1337092,
umls-concept:C1521840,
umls-concept:C1522558,
umls-concept:C1550501,
umls-concept:C1705079,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2603343,
umls-concept:C2697811,
umls-concept:C2745888
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-4-24
|
|
pubmed:abstractText |
Plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and monocyte chemoattractant protein 1 (sMCP-1) are associated with increased risk for future coronary events. However, the effect of statins on these inflammatory markers has hardly been studied. We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:ACTFAST investigators,
pubmed-author:Blanco-ColioLuis MiguelLM,
pubmed-author:EgidoJesúsJ,
pubmed-author:FarsangCsabaC,
pubmed-author:GawAllanA,
pubmed-author:GensiniGianFrancoG,
pubmed-author:LangerAnatolyA,
pubmed-author:LeiterLawrence ALA,
pubmed-author:Martín-VenturaJose LuisJL,
pubmed-author:MartineauPierreP,
pubmed-author:de TeresaEduardoE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
153
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
881-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17452168-Anticholesteremic Agents,
pubmed-meshheading:17452168-Cardiovascular Diseases,
pubmed-meshheading:17452168-Chemokine CCL2,
pubmed-meshheading:17452168-Cholesterol,
pubmed-meshheading:17452168-Diabetes Complications,
pubmed-meshheading:17452168-Dose-Response Relationship, Drug,
pubmed-meshheading:17452168-Female,
pubmed-meshheading:17452168-Heptanoic Acids,
pubmed-meshheading:17452168-Humans,
pubmed-meshheading:17452168-Inflammation,
pubmed-meshheading:17452168-Intercellular Adhesion Molecule-1,
pubmed-meshheading:17452168-Male,
pubmed-meshheading:17452168-Metabolic Syndrome X,
pubmed-meshheading:17452168-Middle Aged,
pubmed-meshheading:17452168-Prospective Studies,
pubmed-meshheading:17452168-Pyrroles,
pubmed-meshheading:17452168-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
|
|
pubmed:affiliation |
Vascular Research Laboratory, Fundación Jimenéz Díaz, Autonoma University, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
